Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenmai injection for cancer-induced fatigue
ChiCTR2100049275Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of shenmai injection in cancer-related fatigue (CRF) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Change from baseline in FACT-F score. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
shenmai injection
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on ChiCTR2100049275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049275.